Bill would require insurers to cover biomarker testing for cancer
Published 3:58 pm Thursday, February 9, 2023
BY SARAH LADD
The Kentucky Lantern
A Kentucky bill filed Tuesday would require health benefit plans to cover biomarker testing with the goal of improving the state’s cancer statistics.
Email newsletter signup
Kentucky Rep. Kimberly Poore Moser, R-Taylor Mill, said prior to filing the legislation that “it’s highly important that we pay attention to science.”
Biomarker testing “is a way to look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer. Each person’s cancer has a unique pattern of biomarkers,” according to the National Cancer Institute.
The American Cancer Society says the testing is “an important step for accessing precision medicine.” It can lead to “improved survivorship and better quality of life for cancer patients.”
The ACS estimates that more than 10,000 Kentuckians will die from cancer this year and 30,000 will be diagnosed with the disease. Kentucky is one of the worst states in the nation for cancer mortality, according to the Centers for Disease Control and Prevention.
“I think it’s time for Kentucky to do something a little cutting edge,” Moser said.
Leah Phillips, a stage four lung cancer survivor from Oldham County, credits biomarker testing with her quality of life.
“A near normal life”
Leah Phillips, a stage four lung cancer survivor from Oldham County, spoke in the Capitol Rotunda Tuesday afternoon. Phillips was diagnosed in December 2019. She did not have a smoking background.
She credited biomarker testing with her quality of life.
“If I had not had biomarker testing,” said Phillips, “I would have been treated like a typical cancer patient with lung cancer…and given chemotherapy.”
Biomarker testing showed her cancer was genetically driven, though. She was eligible for a target therapy drug.
That treatment provided her “a near normal life,” though it is expensive and not universally accessible.
Dr. Doug Flora is the executive medical director of oncology at St. Elizabeth. He said Tuesday that “we’re past the era of chemotherapy for most cancers.” Biomarker testing, added Flora, allows for targeting of cancer’s “achilles heels.”
Barriers to this screening tool mostly impact the “least advantaged people,” he said.
The National Cancer Institute said last year, for example, that Black Americans have higher death rates from many types of cancers than white people.
Additionally, Black women are more likely to die from breast cancer than white women. And colorectal, lung and cervical cancers are more prevalent in Appalachian regions than in urban areas.